Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-24T15:00:58.629Z Has data issue: false hasContentIssue false
  • English
  • Français

Clomipramine and Exposure for Compulsive Rituals: II. Plasma Levels, Side Effects and Outcome

Published online by Cambridge University Press:  29 January 2018

R. S. Stern ,
I. M. Marks ,
D. Mawson  and
D. K. Luscombe
R. S. Stern
Affiliation:
Institute of Psychiatry and the Maudsley Hospital, London; now Consultant Psychiatrist, St George's Hospital, London
I. M. Marks
Affiliation:
The Maudsley and Bethlem Royal Hospital, Professor of Experimental Psychopathology, Institute of Psychiatry, London
D. Mawson
Affiliation:
The Maudsley Hospital and Institute of Psychiatry, London
D. K. Luscombe
Affiliation:
Welsh School of Pharmacy, UWIST, Cathays Park, Cardiff
Get access Rights & Permissions [Opens in a new window]

Summary

Forty obsessive-compulsive ritualizers received nightly placebo or clomipramine up to 225 mgs nocte for 8 months, and received behavioural treatment (exposure in vivo) from weeks 4 to 10. Plasma concentrations of clomipramine and its primary metabolite N-desmethylclomipramine steadily increased over the first 4 weeks of treatment after which they remained relatively steady. Plasma levels correlated significantly with dose and with outcome but not with side effects. Patients with plasma clomipramine levels in the range 100–250 ng/ml and N-desmethylclomipramine levels between 230–550 ng/ml were found to improve significantly more than patients outside these ranges, thus suggesting a therapeutic window for clomipramine and its primary metabolite.

Type
Papers
Information
The British Journal of Psychiatry , Volume 136 , Issue 2 , February 1980 , pp. 161 - 166
Copyright
Copyright © Royal College of Psychiatrists, 1980 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Asberg, M. Cronholm, B., Sjoquist, F. & Tuck, D. (1971) Relationship between plasma level and therapeutic effect of nortriptyline. British Medical Journal, iii, 331.Google Scholar
Asberg, M., Ringberger, V. A., Soquist, F., Thoren, P., Traskman, L. & Tuck, J. R. (1977) Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with clorimipramine. Clinical Pharmacology and Therapeutics, 21, 201–7.Google Scholar
Carnis, G., Godbillon, J. & Metayer, J. P. (1976) Determination of clomipramine and desmethylclomipramine in plasma or urine by double radioisotope derivative technique. Clinical Chemistry, 22, 817.Google Scholar
Jones, R. B. & Luscombe, D. K. (1976) Plasma levels of clomipramine and its N-desmethylmetabolite following oral administration of clomipramine in man. British Journal of Pharmacology, 57, 4308.Google Scholar
Marks, I. M., Stern, R. S., Mawson, D., Cobb, J. & McDonald, R. (1980) Clomipramine and exposure for obsessive-compulsive rituals. I. British Journal of Psychiatry, 136, 1–25.Google Scholar
Montgomery, S. A., McAuley, R., Rani, S. J., Montgomery, D. B., Braithwaite, R. & Dawling, S. (1979) Amitriptyline plasma concentration and clinical response. British Medical Journal, i, 230–1.Google Scholar
Muscettola, G., Goodwin, F. K., Potter, W. Z., Claeys, M. M. & Markey, S. P. (1978) Imipramine and desimipramine in plasma and spinal fluid. Archives of General Psychiatry, 35, 621–5.Google Scholar
Thoren, P., Asberg, M., Conholm, B., Jornestedt, L. & Traskman, L. (1979) Clomipramine treatment of obsessive-compulsive disorder. I: a controlled clinical trial. Archives of General Psychiatry, 000, 000–000.Google Scholar
Ziegler, V. E., Clayton, P. J. & Biggs, J. T. (1977) A comparison study of Amitriptyline and Nortriptyline with plasma levels. Archives of General Psychiatry, 34, 607–15.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.